Form 4: Atlas Venture Funds Execute Sales of Kymera Therapeutics Stock Under 10b5-1 Plans
SEC Form 4
Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. sold shares of Kymera Therapeutics (KYMR) common stock between March 11 and March 13, 2024, under pre-arranged Rule 10b5-1 trading plans.
Summary
- Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. have reported sales of Kymera Therapeutics (KYMR) common stock.
- The sales occurred between March 11, 2024, and March 13, 2024.
- These transactions were executed under pre-arranged Rule 10b5-1 trading plans adopted on January 22, 2024.
- Atlas Venture Fund X, L.P. directly sold shares at weighted average prices ranging from $41.94 to $43.42.
- Atlas Venture Opportunity Fund I, L.P. also directly sold shares at weighted average prices ranging from $41.94 to $43.42.
- Following these transactions, Atlas Venture Fund X, L.P. directly holds 4,676,075 shares.
- Atlas Venture Opportunity Fund I, L.P. directly holds 828,830 shares.
- The general partners of these funds disclaim beneficial ownership except to the extent of their pecuniary interest.
Sentiment
Score: 5
Explanation: The document itself is neutral, simply reporting transactions. The sales themselves could be interpreted as slightly negative, but the use of a 10b5-1 plan suggests they were pre-planned and not necessarily indicative of a negative outlook on the company.
Risks
- The sales by Atlas Venture could exert downward pressure on KYMR's stock price.
- Continued sales under the 10b5-1 plans could further impact the stock price.
Future Outlook
The document does not contain any specific forward-looking statements regarding Kymera Therapeutics' future performance, but it indicates continued sales under existing 10b5-1 trading plans.
Industry Context
Venture capital firms often distribute shares in their portfolio companies to their limited partners or sell shares over time to realize returns on their investments. The use of 10b5-1 plans allows insiders to sell shares in a pre-planned manner, mitigating concerns about insider trading.
Comparison to Industry Standards
- The sales are being conducted under Rule 10b5-1 trading plans, a common practice among corporate insiders and major shareholders to diversify their holdings or distribute shares.
- Other venture capital firms like OrbiMed or NEA also periodically file Form 4s reflecting sales of their portfolio company shares.
- The size and frequency of the sales are typical for venture firms managing large positions in publicly traded companies.
Stakeholder Impact
- Shareholders may react to the news of these sales, potentially leading to short-term price volatility.
- The impact on employees, customers, suppliers, and creditors is likely to be minimal, as these transactions do not directly affect the company's operations.
Key Dates
| Date | Description |
|---|---|
| 2024-01-22 | Rule 10b5-1 trading plans adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. |
| 2024-03-11 | Earliest transaction date for reported sales. |
| 2024-03-11 | Sales of common stock by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. at prices ranging from $42.77 to $43.42. |
| 2024-03-12 | Sales of common stock by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. at prices ranging from $41.94 to $42.52. |
| 2024-03-13 | Sales of common stock by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. at prices ranging from $42.19 to $42.84. |
| 2024-03-13 | Date of signature for the SEC Form 4 filings. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.